Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 3, 2004, Pages 481-487

  Hanft, Alan ^a   Eggleston, Christopher F ^b   Bourgeois, James A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DANTROLENE; OLANZAPINE; VALPROATE SEMISODIUM;

ADOLESCENT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EXPOSURE; HERPES SIMPLEX ENCEPHALITIS; HUMAN; INTENSIVE CARE; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PARANOID SCHIZOPHRENIA; PSYCHOPHARMACOTHERAPY;

ADOLESCENT; BENZODIAZEPINES; CLOZAPINE; HUMANS; MALE; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 8144220683     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2004.14.481     Document Type: Article

References (35)

1. Aboraya A, Schumacher J, Abdalla E, LePage J, McGhee M, Butcher D, Griffin H, Shahda M: Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. W V Med J 2002; 98(2):63-5.
2. Al-Waneen R: Neuroleptic malignant syndrome associated with quetiapine. Can J Psychiatry 2000; 45:764-765.
3. American Psychiatric Association (APA): Diagnostic and statistical manual of mental disorders, 4th ed., text revision (DSM-IV-TR). Washington, DC: 2000, pp. 795-798.
4. Bajjoka I, Patel T, O'Sullivan T: Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med 1997; 30:698-700.
5. Bonwick RJ, Hopwood M, Morris PLP: Neuroleptic malignant syndrome and risperidone: A case report. Aus NZ J Psychiatry 1996; 30:419-421.
6. Bourgeois JA, Babine S, Meyerovich M, Doyle J: A case of neuroleptic malignant syndrome with quetiapine. J Neuropsychiatry Clin Neurosci 2002; 14:87.
7. Brown C, Osterloh J: Multiple complications from recreational ingestion of MDMA ("ecstasy"). JAMA 1987; 258:780-1.
8. Carbone JR: The neuroleptic malignant and serotonin syndromes. Emergency Medicine Clinics of North America 2000; 18:317-324.
9. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Medical Clinics of North America 1993; 77:185-203.
10. Caroff SN, Mann SC, Campbell EC: Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 2000; 30:314-321.
11. Durson SM, Oluboka OJ, Deverajan S, Kutcher SP: High-dose vitamin E plus vitamin B6 treatment of risperidone-related neuroleptic malignant syndrome. J Psychopharmacol 1998; 12:220-221.
12. Ghaziuddin N, Alkhouri I, Champine D, Quinlan P, Fluent T, Ghaziuddin M: ECT treatment of malignant catatonia/NMS in an adolescent: A useful lesson in delayed diagnosis and treatment. J ECT 2002; 18(2):95-98.
13. Glassner Cohen L, Fatalo Q, Taylor Thompson B, Di Centes Bergeron G, Flood JG, Poupolo PR: Olanzapine overdose with serum concentrations. Ann Emerg Med 1999; 34:275-278.
14. Gleason PP, Conigliaro RL: Neuroleptic malignant syndrome with risperidone. Pharmacotherapy 1997; 17:617-621.
15. Gross SR, Barrett SP, Shestowsky JS, Pihl RO: Ectasy and drug consumption patterns: a Canadian rave population study. Canadian J Psychiatry 2002; 47(6):546-551.
16. Gurrera RJ: Sympathoadrenal hyperacrivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156:169-180.
17. Hall KL, Taylor WH, Ware MR: Neuroleptic malignant syndrome due to olanzapine. Psychopharm Bull 2001; 35(3):49-54.
18. Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry 1998; 155:1113-1116.
19. Jangbahadoer Sing K, Ramaekers GMGI, Van Harten PN: Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry 2002, 159:149-150.
20. Johnson V, Bruxner: Neuroleptic malignant syndrome associated with olanzapine. Aus NZ J Psychiatry 1998; 32:884-886.
21. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK: Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. Ann Pharmacother 1999; 33:623-630.
22. Lee MS, Lee HJ, Kim L: A case of delayed NMS induced by risperidone. Psychiatr Serv 2000; 51:254-255.
23. Lee SI, Klesmer J, Hirsch BE: Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: A case report. Psychosomatics 2000; 41:453-454.
24. Levenson JL: Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145.
25. Meltzer HY, Cola PA, Parsa M: Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996; 15:395-405.
26. Newman M, Anjee A, Jampala C: Atypical neuroleptic malignant syndrome associated with risperidone treatment. Am J Psychiatry 1997; 154:1475.
27. Pelonero AL, Levenson JL, Pandurangi AK: Neuroleptic malignant syndrome: A review. Psychiatric Services 1998; 49:1163-1172.
28. Reeves RR, Mack JE, Torres RA: Neuroleptic malignant syndrome during a change from haloperidol to risperidone. Ann Pharmacother 2001; 35:698-701.
29. Robb AS, Chang W, Lee HK, Cook MS: Case study: risperidone-induced neuroleptic malignant syndrome in an adolescent. J Child Adolescent Psychopharmacol 2000; 10:327-330.
30. Rosebush P, Stewart T, Gelenberg A: Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in fifteen patients. Journal of Clinical Psychiatry 1989; 50:295-298.
31. Rundell JR, Wise MG: Concise guide to consultation psychiatry, 3rd ed. Washington, DC: American Psychiatric Press, Inc., 2000, pp. 180-190.
32. Sechi G, Agnetti V, Masuri R, Deiana GA, Pugliatti M, Paulus KS, Rosati G: Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24:1043-1051.
33. Stanley AK, Hunter J: Possible neuroleptic malignant syndrome with quetiapine. Br J Psychiatry 2000; 176:497.
34. Swanson SL, Price WA, McEvoy JP: Effects of concomitant risperidone and lithium treatment. Am J Psychiatry 1995; 152:1096.
35. Whalley N, Diaz P, Howard J: Neuroleptic malignant syndrome associated with the use of quetiapine. Can J Hosp Pharmacy 1999; 52:112.